evipedia.ai
← Back

Male HRT for Health & Longevity

Evidence Review created on 09/14/2026 using AI4L / Opus 5

Also known as: Testosterone Replacement Therapy, TRT, Androgen Replacement Therapy, Male Hormone Replacement Therapy, Male Hormone Restoration, Testosterone Therapy, Androgen Therapy

Motivation

Male hormone replacement therapy is the supervised administration of testosterone, the principal male sex hormone, to men whose own production has dropped below the range typical of healthy young adults. Testosterone acts most visibly on muscle, bone and sexual desire, so a sustained shortfall touches several systems at once. Interest has widened well past men with a diagnosed disorder, reaching men who treat hormonal decline as one of the changeable features of growing older.

Average testosterone concentrations drift downward from midlife onward, and a sizeable minority of older men fall below the reference range while reporting fatigue, low desire and loss of muscle. Injectable and topical preparations have existed for decades, yet prescribing has climbed steeply in several countries, helped by direct-to-consumer clinics. Whether restoring a hormone that falls with age counts as correction or as enhancement remains genuinely disputed.

This review examines what controlled human evidence shows about long-term testosterone administration in men: which outcomes it changes and by how much, which harms it carries, how it is given, monitored and stopped, and where the evidence base is still thin or contested.

Benefits - Risks - Protocol - Conclusion

High-level overviews of male hormone replacement therapy (male HRT, also called testosterone replacement therapy or TRT — supplying testosterone from outside the body) from clinicians and researchers who treat or study it directly.

No directly relevant content on male hormone replacement was found on lifespan.io, whose testosterone coverage is limited to observational and Mendelian-randomization studies (which use inherited gene variants to probe cause) of endogenous hormone levels rather than the therapy itself.

Grokipedia

  • Testosterone Replacement Therapy

    A broad reference entry covering diagnostic thresholds, the available preparations, monitoring parameters and the contested cardiovascular and prostate safety literature, useful as an orientation before reading the primary trials.

Examine

Examine.com has no dedicated article on male hormone replacement therapy. Its testosterone coverage is an outcome page cataloguing the supplements, foods and diets shown to shift testosterone concentrations, a condition entry on low testosterone, and research-feed summaries of individual studies; none reviews the therapy itself.

Because testosterone is a prescription-only controlled medication rather than a supplement, this absence is expected: Examine.com does not typically cover prescription medications.

ConsumerLab

ConsumerLab.com has no article on male hormone replacement therapy. Its testosterone-related content consists entirely of product reviews and answers about over-the-counter supplements marketed as testosterone boosters.

ConsumerLab tests dietary supplements rather than prescription drugs, so this absence is expected: ConsumerLab does not typically cover prescription medications.

Systematic Reviews

Pooled analyses of randomized trials covering the main claimed benefits of testosterone therapy and its principal documented harms.

Mechanism of Action

Testosterone is a steroid hormone made mainly by the Leydig cells of the testes under control of luteinizing hormone (LH, the pituitary signal telling the testes to make testosterone) and follicle-stimulating hormone (FSH, the pituitary signal driving sperm production). It circulates largely bound to sex hormone-binding globulin (SHBG, the carrier protein for sex steroids), leaving a small free fraction available to tissues. Free testosterone enters cells and either binds the androgen receptor (AR, the switch turning on androgen-responsive genes), is converted by 5-alpha-reductase to dihydrotestosterone (DHT, a more potent androgen acting on skin, hair and prostate), or is converted by aromatase to estradiol, which mediates much of testosterone’s effect on bone and sexual desire.

Replacement supplies testosterone from outside the body, restoring receptor occupancy in muscle, bone, marrow and brain. Because the hypothalamus and pituitary sense the restored concentration, they cut LH and FSH output, so the testes shrink their own production and sperm output falls. Exogenous testosterone substitutes for, rather than stimulates, native function.

Native testosterone has a circulating half-life of minutes, so clinical products are esters or modified forms: enanthate roughly 4.5 days, cypionate roughly 8 days, injected undecanoate roughly 34 days, gels effectively daily. Metabolism is hepatic, via CYP3A4 (a liver enzyme clearing many drugs) and UGT2B17 (which tags it for excretion).

A competing mechanistic reading holds that low testosterone in older men is largely a marker of illness and excess fat rather than a driver, so replacement corrects a signal rather than a cause.

Historical Context & Evolution

Testosterone was isolated and synthesized in 1935, and injectable esters entered clinical use shortly afterwards for classical hypogonadism (deficiency from disease of the testes or pituitary): damaged testes, pituitary tumors or Klinefelter syndrome (an extra X chromosome), in whom replacement is uncontested. Through the mid-twentieth century it was also tried, with poorly documented results, for aging-related complaints under the label of the male climacteric.

The modern expansion began when transdermal gels reached the market around 2000. Prescribing in the United States rose several-fold that decade, much of it to middle-aged men with symptoms and borderline concentrations rather than structural testicular disease. Two observational analyses in 2013 and 2014 reported more cardiovascular events among treated men, prompting a regulatory warning and a sharp fall in prescribing.

Those observational reports were widely described as discredited, but the primary criticisms were methodological rather than refutations of a causal link: small event numbers, coding errors and confounding by indication (sicker men being the ones treated). The question was settled, to the extent it has been, only by randomized data. The T-Trials in 2016 and 2017 measured seven outcomes in men over 65; TRAVERSE, funded by AbbVie, which markets a testosterone gel, enrolled 5,246 men at elevated cardiovascular risk and reported non-inferiority (no worse than placebo) for major cardiac events in 2023.

Opinion moved from enthusiasm to alarm and back toward cautious acceptance, while unresolved signals for fractures, atrial rhythm disturbance and clotting emerged from the same trial that reassured on heart attacks.

Expected Benefits

High 🟩 🟩 🟩

Sexual Desire and Erectile Function

Restoring testosterone raises sexual desire, spontaneous sexual thoughts and the frequency of sexual activity, with a smaller effect on erectile rigidity. The proposed mechanism is central: androgen and estradiol signaling in hypothalamic circuits that set libido. Individual data from 3,431 men in 17 randomized trials show a gain that reaches the minimal clinically important difference for mild erectile dysfunction, independent of age, obesity, diabetes or how low the baseline concentration was. Men who start more symptomatic finish at a lower absolute level.

Magnitude: Mean difference versus placebo of 5.52 points on the 15-item International Index of Erectile Function (95% confidence interval — the band within which the true effect most likely sits — 3.95 to 7.10) and 2.14 points on its erectile-function subscore, per Hudson et al., 2023.

Lean Mass Gain and Fat Mass Loss

Testosterone increases muscle protein synthesis and the recruitment of muscle stem cells while steering precursor cells away from becoming fat cells, shifting body composition toward lean tissue. Fifty-nine randomized trials in 5,078 men found consistent fat-mass reduction and lean-mass gain without change in total body weight. A controlled graded-dose experiment in young men, in which native production was switched off pharmacologically, showed the response scales with the dose administered rather than plateauing at replacement concentrations.

Magnitude: Fat-free mass rose 3.4, 5.2 and 7.9 kg over 20 weeks at 125, 300 and 600 mg of testosterone enanthate weekly, tracking log testosterone concentration, per Bhasin et al., 2001.

Bone Mineral Density and Estimated Bone Strength

Testosterone raises bone density mainly through aromatization to estradiol, which restrains the bone-resorbing osteoclast. A one-year placebo-controlled trial in 211 men aged 65 and over measured volumetric density by quantitative computed tomography and estimated strength by finite-element analysis, finding larger gains in the spine than the hip and in trabecular than cortical bone. A meta-analysis of 36 studies confirms the spine effect and shows it is largest in men who start lowest and treat longest. Whether this translates into fewer fractures is addressed under Risks.

Magnitude: Spine trabecular volumetric density rose 7.5% versus 0.8% on placebo, a treatment effect of 6.8% (95% confidence interval 4.8 to 8.7), with estimated spine trabecular strength up 8.5%, per Snyder et al., 2017.

Correction of Unexplained Anemia

Testosterone stimulates red blood cell production and mobilizes iron for hemoglobin synthesis, correcting anemia (a shortage of red blood cells or hemoglobin) that has no other identified cause. In a placebo-controlled trial within the T-Trials, older men with unexplained anemia responded strongly, and men with anemia of known cause also improved. A separate randomized trial within the TRAVERSE program replicated the finding in middle-aged and older men. The same mechanism produces the erythrocytosis (excess red cells) listed among the risks, so the therapeutic window is narrow.

Magnitude: Hemoglobin rose by 1.0 g/dL or more in 54% of treated men with unexplained anemia versus 15% on placebo (adjusted odds ratio — the multiple by which the odds of responding rose — 31.5, 95% confidence interval 3.7 to 277.8), per Roy et al., 2017.

Improved Glucose Tolerance and Reduced Progression to Type 2 Diabetes

Testosterone improves insulin sensitivity, partly by reducing visceral fat and partly through direct effects on muscle glucose uptake. A two-year randomized trial in 1,007 men with impaired glucose tolerance or newly diagnosed diabetes, all enrolled in a lifestyle program, found that injected testosterone undecanoate cut progression beyond the lifestyle effect, independent of baseline testosterone. A meta-analysis of 59 trials likewise reports lower fasting glucose and insulin resistance, with the largest effect in younger men and those with metabolic disease.

Magnitude: Two-hour glucose of 11.1 mmol/L or above occurred in 12% of treated men versus 21% on placebo (relative risk — the treated rate divided by the placebo rate — 0.59, 95% confidence interval 0.43 to 0.80), per Wittert et al., 2021, a trial part-funded by Bayer and Eli Lilly, both testosterone manufacturers.

Medium 🟩 🟩

Men with low testosterone commonly report fatigue, reduced drive and a diminished sense of wellbeing, and pooled individual data show these composite symptom scores improve on treatment. The effect is modest and smaller than the sexual-function response. A separate two-year randomized trial in men who were overweight found gains in some psychosocial and quality-of-life domains that were partly attributable to the accompanying weight loss rather than the hormone itself, which is why this sits below the High tier despite multiple trials.

Magnitude: Aging Males’ Symptoms and several Short Form Survey subscores improved versus placebo in men with baseline testosterone below 12 nmol/L treated for twelve months; the pooled analysis reports significance but gives no interpretable outcome figure for vitality, per Hudson et al., 2023.

Muscle Strength and Physical Performance ⚠️ Conflicted

Strength gains follow the lean-mass gains, but translation into walking speed, stair climbing and self-reported physical function has been inconsistent. Graded-dose work shows leg press strength and leg power rise in proportion to testosterone concentration. A trial in older men with mobility limitation found strength and stair-climbing gains, yet the T-Trials Physical Function Trial missed its primary walking-distance endpoint in the physically limited subgroup while reaching it across all participants. Net reading: strength improves reliably, everyday function only in some populations.

Magnitude: Leg press strength and leg power increased in direct proportion to achieved testosterone concentration across five weekly doses from 25 to 600 mg; the direction holds across dose but the trials give no pooled outcome figure for everyday physical function, per Bhasin et al., 2001.

Low 🟩

Depressive Symptoms ⚠️ Conflicted

An early meta-analysis of small trials reported an antidepressant effect. Larger datasets do not support it: pooled individual data found no change on the Beck Depression Inventory, and a TRAVERSE substudy confined benefit to subthreshold symptoms. Net reading: testosterone does not treat clinical depression, though low-grade mood complaints may lift.

Magnitude: Not quantified in available studies. The trials that measured depressive symptoms report null or inconsistent effects rather than a consistent effect size, per Bhasin et al., 2024.

Lower Cardiovascular Event Rate ⚠️ Conflicted

Observational cohorts repeatedly find fewer heart attacks and lower mortality among treated men; randomized trials find no such advantage. The likely explanation is confounding by indication. Net reading: the protective signal looks like an artifact of observational design, and randomized data support safety rather than benefit.

Magnitude: Observational studies show significant reductions in arterial thrombosis, myocardial infarction and mortality, while the randomized subset of the same analysis shows no effect on mortality (odds ratio 0.70, 95% confidence interval 0.20 to 2.38), per Cannarella et al., 2024.

Speculative 🟨

Extension of Healthy Lifespan

Men with low endogenous testosterone die earlier. No trial has been powered to test whether replacement changes lifespan, so the basis is observational association and mechanism only.

Preservation of Cognitive Function in Later Life

Androgen receptors sit in hippocampus and prefrontal cortex. The only adequately powered trial found no memory or executive-function benefit at one year, so longer-horizon effects rest on mechanism alone.

Benefit-Modifying Factors

  • Baseline testosterone concentration: Symptom relief is largest in men starting well below the reference range. Bone density gains in pooled analyses appear only when baseline total testosterone is under 12 nmol/L, and metabolic gains scale similarly.

  • Androgen receptor CAG repeat length: The number of CAG triplet repeats in the androgen receptor gene sets receptor sensitivity. Longer repeats mean a weaker response at the same hormone concentration, so identical dosing produces unequal tissue effects.

  • Aromatase activity and adiposity: CYP19A1 (the gene for aromatase, the enzyme converting testosterone to estradiol) is highly expressed in fat tissue. Men carrying more fat convert more of the dose to estradiol, altering the balance of bone benefit against breast tissue growth.

  • Sex hormone-binding globulin level: A high carrier-protein concentration leaves less free hormone at any given total, so men with high values need higher totals for the same tissue effect. Insulin resistance lowers it; aging and thyroid excess raise it.

  • Sex-based differences: The evidence base is male-only for this indication, so no within-male sex comparison exists. Female testosterone therapy uses roughly one-tenth the dose for different endpoints and is outside this review’s scope.

  • Pre-existing conditions: Obesity, poorly controlled diabetes, obstructive sleep apnea (repeated breathing pauses in sleep) and opioid use all suppress endogenous production, so treating the underlying condition may raise testosterone without replacement and changes what replacement adds.

  • Age at initiation: Men at the older end respond on sexual desire and bone much as younger men do, but reach lower absolute function scores because they start more symptomatic, and they show larger red-cell responses to the same dose.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Erythrocytosis and Elevated Hematocrit

Testosterone stimulates red cell production and suppresses hepcidin (the hormone that restricts iron release), raising hematocrit (the fraction of blood volume occupied by red cells). This is the most common dose-limiting effect and the usual reason for dose reduction or deliberate blood removal. The response is linear with dose and markedly larger in older men. Injectable esters producing high peaks raise it more than transdermal gels. Untreated, it thickens blood and has been linked in registry data to more thrombotic events in the first year of therapy.

Magnitude: Treated men were 3.7 times as likely as placebo recipients to exceed 50% hematocrit (odds ratio 3.69, 95% confidence interval 1.82 to 7.51) per Calof et al., 2005; separately, 22% of men on injected undecanoate exceeded 54% within two years versus 1% on placebo, per Wittert et al., 2021.

Suppression of Sperm Production and Infertility

Exogenous testosterone shuts down pituitary LH and FSH release, collapsing the intratesticular testosterone concentration on which sperm production depends. Most men become severely oligospermic or azoospermic (very few sperm, or none) within months; the effect underpins its historical use in male contraceptive trials. Recovery after stopping usually takes several months to two years and is not guaranteed, particularly after prolonged use or in men with impaired baseline fertility.

Magnitude: Intratesticular testosterone falls by roughly 94% within days of starting exogenous testosterone with gonadotropin suppression, per Coviello et al., 2005; contraceptive trials achieved azoospermia in the large majority of participants.

Suppression of the Body’s Own Testosterone Production

The same feedback loop that halts sperm production shuts down Leydig cell output, causing testicular volume loss and making the man dependent on the exogenous supply. The evidence basis is controlled gonadotropin-suppression experiments together with recovery series following contraceptive and replacement regimens. Stopping abruptly leaves concentrations below the pre-treatment baseline for weeks to months, with fatigue, low mood and loss of libido during the gap. Recovery of the axis is slower in older men and after long exposure; some men do not return to baseline.

Magnitude: Suppression is essentially complete at replacement doses and above, and recovery slows with longer exposure and older age; the recovery literature reports this direction and timeline but gives no outcome figure, per Crosnoe et al., 2013.

Reduced High-Density Lipoprotein Cholesterol

Testosterone increases hepatic lipase (a liver enzyme that breaks down circulating lipoprotein particles) activity, lowering high-density lipoprotein cholesterol (HDL, the lipoprotein fraction carrying cholesterol away from tissues). The change is dose-dependent and appears consistently across trials. Its clinical weight is uncertain: drug-induced HDL lowering has not reliably predicted cardiovascular events, and the large randomized safety trial found no excess of heart attacks despite the lipid shift.

Magnitude: Weighted mean difference of −0.49 mg/dL across 51 trials (95% confidence interval −0.85 to −0.13) per Fernández-Balsells et al., 2010, with steeper falls at supraphysiological doses.

Acne and Oily Skin

Dihydrotestosterone acts on the skin’s oil glands, increasing oil output and the build-up of dead cells that plugs follicles. The evidence basis is pooled adverse-event data from randomized trials together with product labelling. Acne, scalp and back oiliness appear early, are dose-related and concentrate in the first months. They reverse on dose reduction and respond to standard dermatological treatment. Prevalence is higher with peak-and-trough injectable regimens than with daily transdermal delivery.

Magnitude: Acne and oily skin rise with dose and are concentrated in the first three months and in peak-and-trough injectable regimens; the pooled analyses report this direction as a consistent excess but give no outcome figure, per Fernández-Balsells et al., 2010.

Medium 🟥 🟥

Atrial Fibrillation

The largest cardiovascular safety trial recorded more atrial fibrillation (an irregular, often rapid heart rhythm originating in the upper chambers) in the testosterone arm than on placebo over a mean 33 months. Proposed mechanisms include atrial structural remodeling and fluid retention. The finding came from a prespecified secondary safety list rather than a powered endpoint, so it is a single-trial signal rather than a confirmed effect.

Magnitude: Atrial fibrillation occurred in 3.5% of men on testosterone versus 2.4% on placebo over a mean 33 months in men aged 45 to 80 at elevated cardiovascular risk, per Lincoff et al., 2023, a trial funded by AbbVie, which markets testosterone gel.

Increased Clinical Fracture Rate

Despite raising bone density, testosterone produced more fractures than placebo in a prespecified fracture substudy of 5,204 men followed a median 3.19 years. Every fracture category trended the same way. The mechanism is unexplained; increased physical activity, altered balance or a density-independent effect on bone quality have all been proposed. This directly contradicts the density findings and is the single most surprising safety result in the field.

Magnitude: Clinical fracture occurred in 3.50% on testosterone versus 2.46% on placebo (hazard ratio — the ratio of event rates over the follow-up period — 1.43, 95% confidence interval 1.04 to 1.97), per Snyder et al., 2024.

Pulmonary Embolism and Venous Thromboembolism ⚠️ Conflicted

The large safety trial reported more pulmonary embolism (a clot lodged in the lung circulation) on testosterone, and product labels carry a clotting warning. Pooled analyses of randomized trials, however, find no significant excess of venous thromboembolism (clots forming in the deep veins) or pulmonary embolism, and observational data point the other way. Plausible mechanisms are raised hematocrit and altered clotting factors. Net reading: an absolute risk small enough that only the largest trial detected it, concentrated in men whose hematocrit rises steeply.

Magnitude: Pooled randomized data give an odds ratio of 1.42 for venous thromboembolism (95% confidence interval 0.22 to 9.03) and 1.38 for pulmonary embolism (0.27 to 7.04), neither significant, per Cannarella et al., 2024.

Elevated Blood Pressure

Testosterone products raise blood pressure modestly, an effect the United States regulator singled out for labeling. Sodium and water retention and the rise in hematocrit both contribute. Ambulatory monitoring in 138 hypogonadal men on an oral formulation quantified the shift, and the men whose red cell mass rose most had the largest pressure increases, linking the two harms mechanistically.

Magnitude: Twenty-four-hour systolic pressure rose 3.8 mmHg and awake systolic 5.2 mmHg after four months; in the top quartile of hematocrit change the systolic rise averaged 8.3 mmHg, per White et al., 2021.

Prostate Events and Rising Prostate-Specific Antigen

Testosterone increases prostate volume and prostate-specific antigen (PSA, a protein whose blood level rises with prostate size, inflammation or cancer), triggering biopsies and urological referrals. Pooled trial data show more prostate events overall on treatment, driven by detection rather than a demonstrated rise in cancer incidence; individual components were not separately significant. Randomized safety data since have not shown an excess of high-grade prostate cancer.

Magnitude: Combined prostate events occurred more often on testosterone (odds ratio 1.78, 95% confidence interval 1.07 to 2.95), per Calof et al., 2005.

Gynecomastia and Breast Tenderness

Gynecomastia (growth of male breast gland tissue) follows aromatization of the administered dose to estradiol, which stimulates breast glandular tissue and produces tenderness and, less often, visible enlargement. It is dose-related, more common in men with more body fat and higher aromatase activity, and largely reversible early. The evidence basis is pooled adverse-event data from randomized trials together with product labelling. Established fibrotic tissue does not regress with dose reduction and requires surgery.

Magnitude: Breast tenderness and enlargement increase with dose and with body fat, the tissue where aromatase activity is highest; the pooled analyses report this direction only and give no outcome figure, per Fernández-Balsells et al., 2010.

Acute Kidney Injury

The large safety trial recorded more acute kidney injury (a sudden fall in the kidneys’ filtering capacity) in the testosterone arm. No mechanism has been established; volume shifts, blood pressure changes and increased muscle turnover have been proposed. Like the atrial fibrillation signal it comes from a secondary safety list in one trial and has not been replicated.

Magnitude: Acute kidney injury occurred in 2.3% of men on testosterone versus 1.5% on placebo, in the same population of men with pre-existing or high cardiovascular risk, per Lincoff et al., 2023.

Low 🟥

Worsening of Obstructive Sleep Apnea ⚠️ Conflicted

A randomized trial in obese men with severe sleep apnea found breathing disturbance worsened at seven weeks but not at eighteen, suggesting a transient effect. Product labels nonetheless warn about it. Net reading: a short-lived worsening in men who already have significant apnea, not a general risk.

Magnitude: The oxygen desaturation index worsened by 10.3 events per hour (95% confidence interval 0.8 to 19.8) and time with oxygen saturation below 90% by 6.1 percentage points at seven weeks, with neither difference remaining at eighteen weeks, per Hoyos et al., 2012.

Mood Lability and Irritability

Reports of irritability, aggression and emotional volatility come mainly from uncontrolled series, case reports and supraphysiological dosing rather than from controlled replacement trials, where mood measures are largely neutral. Peak-and-trough injectable regimens are the usual context.

Magnitude: Not quantified in available studies. Controlled trials at replacement doses did not measure irritability as a prespecified endpoint, so only uncontrolled reports exist, per Bhasin et al., 2001.

Secondary Transfer of Topical Testosterone

Gels and creams transfer by skin contact to partners and children, producing virilization (the appearance of male traits such as body hair) in them. The evidence is post-marketing case reports, which prompted a boxed warning. Covering the application site and washing hands avoids it; injectable and oral forms are unaffected.

Magnitude: Not quantified in available studies. Only post-marketing case reports exist, with no denominator from which an incidence could be derived, per Bhasin et al., 2018.

Accelerated Male-Pattern Hair Loss

Dihydrotestosterone shrinks scalp follicles in susceptible men, so replacement can bring forward a recession that would have arrived later. Product labels list male-pattern baldness among adverse reactions, but controlled trials did not track scalp coverage, leaving only labeling and clinical report. Stopping does not reverse it.

Magnitude: Not quantified in available studies. No controlled trial has measured scalp hair density on testosterone therapy, so the effect rests on labeling and clinical observation, per Bhasin et al., 2018.

Pulmonary Oil Microembolism and Anaphylaxis

Injected testosterone undecanoate can release oil droplets into the lung circulation (pulmonary oil microembolism), causing cough, breathlessness and chest tightness within minutes, and rarely anaphylaxis (a severe whole-body allergic reaction). The evidence is post-marketing reports, which prompted a boxed warning and a 30-minute observation period. Most episodes resolve unaided.

Magnitude: Twenty-eight confirmed events across 90,092 distributed doses over 4.3 years, a spontaneously reported rate below 0.1% per injection, with most resolving within 30 minutes, per Pastuszak et al., 2020.

Speculative 🟨

Acceleration of Occult Prostate Cancer

Androgen deprivation shrinks prostate cancer, so the reverse has long been feared. No randomized trial has shown accelerated growth of undetected disease; the concern rests on mechanism and isolated case series.

Cardiac Structural Remodeling

Androgen receptors are expressed in cardiac muscle, and supraphysiological exposure thickens the left ventricle in animal work and in bodybuilder case series. No controlled human data at replacement doses exist.

Risk-Modifying Factors

  • JAK2 and HFE variants: A JAK2 V617F mutation (a driver of polycythemia, too many red cells) or variants in HFE (the gene governing dietary iron absorption) compounds the red-cell rise, turning a manageable hematocrit increase into a thrombotic hazard.

  • 5-alpha-reductase and aromatase genotype: SRD5A2 variants (the gene for the enzyme making dihydrotestosterone) shift risk toward acne and prostate effects; high-activity CYP19A1 variants shift it toward breast tissue growth and fluid retention.

  • Baseline hematocrit and ferritin: Starting above 50% hematocrit, or with high iron stores, sharply shortens the time to a dose-limiting red-cell rise and to the blood-pressure increase that accompanies it.

  • Baseline prostate-specific antigen: A raised starting value increases the chance that treatment-related prostate growth triggers biopsy, and marks men in whom urological assessment precedes therapy.

  • Sex-based differences: Erythrocytosis, prostate events and fertility suppression are male-specific harms with no female counterpart; the acne, lipid and mood effects occur in both sexes but at far lower female doses.

  • Pre-existing conditions: Untreated severe sleep apnea, heart failure, a prior venous clot, thrombophilia (an inherited clotting tendency) and active prostate or breast cancer each convert a common side effect into a serious one.

  • Age: Older men show larger hemoglobin and hematocrit responses to an identical dose, and carry the fracture, atrial rhythm and kidney signals seen in the trial population aged 45 to 80.

Key Interactions & Contraindications

  • Warfarin and other vitamin K antagonists (caution): Testosterone potentiates the anticoagulant effect, raising bleeding risk. Standard practice is a repeat international normalized ratio within one to two weeks of starting or changing dose, with downward adjustment.

  • Insulin and sulfonylureas such as glipizide and glyburide (monitor): Improved insulin sensitivity can cause hypoglycemia (blood sugar falling too low) at unchanged doses. Pre-emptive reduction of the glucose-lowering medication, with monitoring over the first three months, is the usual mitigation.

  • SGLT2 inhibitors, the sodium-glucose cotransporter-2 blockers such as empagliflozin and dapagliflozin (monitor): Both raise hematocrit, and combined use increases erythrocytosis risk. Hematocrit is checked at six to eight weeks rather than three months.

  • 5-alpha-reductase inhibitors such as finasteride and dutasteride (caution): They block conversion to dihydrotestosterone, blunting prostate and scalp effects but also suppressing prostate-specific antigen by roughly half, which masks a rising value.

  • Aromatase inhibitors such as anastrozole and letrozole (caution): Used off-label to limit estradiol, they can drive it too low, causing bone loss, joint pain and loss of libido. Their use is restricted to documented symptomatic excess.

  • Corticosteroids including prednisone (caution): Additive sodium and water retention raises the chance of edema and blood pressure elevation, particularly in men with heart or kidney impairment.

  • Opioids including oxycodone and morphine (monitor): Chronic opioid use itself suppresses the hormonal axis. Tapering the opioid may restore testosterone, altering the dose required or the need for therapy.

  • Iron supplements and erythropoiesis-stimulating agents (caution): Additive stimulation of red cell production. Routine iron is withheld unless deficiency is documented, and hematocrit is rechecked after any iron course.

  • Over-the-counter non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen (monitor): Additive sodium retention and blood pressure elevation, and additive kidney stress given the acute kidney injury signal. Chronic daily use is limited on that basis.

  • Over-the-counter decongestants such as pseudoephedrine (caution): Additive blood pressure elevation on top of the systolic rise testosterone produces. Saline or intranasal steroid alternatives are preferred.

  • Supplements that raise free testosterone such as boron, tongkat ali and ashwagandha (monitor): Additive to the prescribed dose, pushing concentrations above target. They are stopped before a dose is established, or accounted for in titration.

  • Supplements that raise blood pressure or red cell mass such as high-dose licorice root and erythropoietin-mimetic products (caution): Additive to two of testosterone’s documented effects; licorice also causes potassium loss.

  • Other interventions – phlebotomy and blood donation (mitigating): Deliberate blood removal is the standard countermeasure for treatment-related erythrocytosis; every 500 mL lowers hematocrit by roughly 3 percentage points.

Populations who should avoid Male HRT:

  • Men with active or previously untreated prostate cancer, or with prostate-specific antigen above 4 ng/mL (above 3 ng/mL where risk is elevated) pending urological assessment
  • Men with male breast cancer
  • Men with baseline hematocrit above 54%, or with untreated primary polycythemia
  • Men with untreated severe obstructive sleep apnea (apnea-hypopnea index above 30 events per hour)
  • Men with uncontrolled heart failure, New York Heart Association Class III or IV
  • Men within 3 to 6 months of myocardial infarction or stroke
  • Men seeking conception within the following 12 months, or with a known thrombophilia such as factor V Leiden
  • Men with severe untreated lower urinary tract symptoms, International Prostate Symptom Score above 19

Risk Mitigation Strategies

  • Divided dosing by the subcutaneous route: Dividing a weekly ester dose into two or three subcutaneous administrations flattens peaks and limits the hematocrit rise, acne and mood swings that follow high post-injection concentrations.

  • A defined hematocrit ceiling: Protocols reduce the dose when hematocrit passes 52%, and interrupt therapy or use phlebotomy above 54%, the threshold at which thrombotic and blood-pressure risk rises steeply.

  • Early rather than annual hematocrit checks: Measurement at 6 to 8 weeks, 3 months and 6 months, then every 6 to 12 months, because erythrocytosis develops fastest in the first year and in older men.

  • Prostate status established before starting: Prostate-specific antigen and a digital rectal examination at baseline and again at 3 to 12 months, with urological referral when the value rises more than 1.4 ng/mL within a year.

  • Sperm banking before the first dose: Semen cryopreservation removes the fertility consequence of axis suppression, which can persist for months to years after stopping.

  • Co-administered chorionic gonadotropin to preserve testicular function: 500 to 1,500 IU (international units) subcutaneously two to three times weekly maintains intratesticular testosterone, limiting testicular atrophy and the depth of sperm suppression.

  • Sleep apnea treated before, not after: Diagnosing and treating significant apnea first prevents the transient worsening of breathing disturbance and removes an independent driver of raised hematocrit.

  • Home blood pressure monitoring: Weekly readings for the first 3 months catch the 4 to 5 mmHg systolic rise, and larger increases in men whose red cell mass climbs fastest, before it compounds existing hypertension.

  • The lowest dose reaching a mid-range trough: Targeting 500 to 700 ng/dL rather than the upper limit limits the dose-dependent harms — erythrocytosis, HDL cholesterol fall, acne — that scale with concentration.

  • Aromatase inhibitors reserved for documented symptomatic excess: Routine use to suppress estradiol causes bone loss and joint pain; treating breast tenderness by lowering the testosterone dose avoids that trade.

Therapeutic Protocol

  • Diagnostic threshold: Two separate fasting morning total testosterone measurements below roughly 300 ng/dL (10.4 nmol/L) alongside consistent symptoms, with luteinizing hormone and prolactin to distinguish testicular from pituitary causes.

  • Conventional endocrinology approach: The Endocrine Society guideline confines therapy to men with unequivocal biochemical deficiency plus symptoms, targeting the mid-normal range. The society’s members are the physicians who prescribe and monitor the therapy.

  • Longevity and men’s-health-clinic approach: Practitioners such as Peter Attia treat symptomatic men with low-normal values, target the upper half of the range, and add chorionic gonadotropin routinely. Such clinics derive revenue from prescribing.

  • Injectable esters, the most used regimen: Testosterone cypionate or enanthate 100 to 200 mg weekly intramuscularly, or more commonly 50 to 100 mg weekly divided into two subcutaneous administrations for steadier concentrations.

  • Transdermal gel: 1.62% gel, 20.25 to 81 mg of testosterone applied once daily to shoulders or upper arms, titrated on a trough measurement; avoids peaks but carries the transfer risk.

  • Long-acting and oral alternatives: Injected testosterone undecanoate 750 to 1,000 mg every 10 to 14 weeks; oral undecanoate 158 to 396 mg twice daily with food; subcutaneous pellets every 3 to 6 months.

  • Best time of day: Morning administration for gels and oral forms mimics the natural peak and matches the timing of trough monitoring; injection timing is arbitrary beyond keeping intervals consistent.

  • Half-life and its consequences: Enanthate roughly 4.5 days, cypionate roughly 8 days, injected undecanoate roughly 34 days, gels effectively daily. Longer esters mean slower titration and slower washout if problems arise.

  • Single versus split dosing: Splitting weekly ester doses into two or three smaller subcutaneous administrations reduces peak-to-trough swing, which limits erythrocytosis and mood volatility without changing the weekly total.

  • Genetic influences on dose: Long androgen receptor CAG repeats reduce receptor sensitivity and may require a higher trough; SRD5A2 and CYP19A1 variants shift the balance of dihydrotestosterone and estradiol produced from a given dose.

  • Sex-based differences: Female testosterone therapy uses roughly a tenth of the male dose for different endpoints; no male dosing conclusion transfers from it, and this review’s protocol applies to men only.

  • Age-related adjustment: Men above 65 show larger red-cell responses at identical doses, so starting near the bottom of the range with earlier hematocrit checks is standard at the older end.

  • Baseline biomarkers shaping response: A high sex hormone-binding globulin raises the total concentration needed for the same free hormone; a very low baseline predicts the largest symptom response.

  • Conditions altering the regimen: Obesity increases conversion to estradiol; sleep apnea and polycythemia lower the hematocrit ceiling; chronic opioid use may resolve on tapering, removing the indication.

Discontinuation & Cycling

  • Intended duration: Therapy for confirmed hypogonadism is treated as indefinite, because the deficiency it corrects does not resolve; stopping returns concentrations to baseline or below.

  • Withdrawal effects: Fatigue, low mood, loss of libido and reduced motivation appear within weeks of stopping and persist until the axis recovers, which takes months and occasionally longer.

  • Tapering: Tapering the testosterone dose alone does not speed axis recovery. Restart protocols instead use chorionic gonadotropin 1,500 to 3,000 IU every other day with clomiphene 25 to 50 mg, which blocks estrogen feedback on the pituitary.

  • Cycling: Cycling is not used for efficacy; the therapy does not lose effect with continuous use, and interruptions reintroduce symptomatic deficiency without benefit.

  • Trial of discontinuation: Men who started on borderline values or whose underlying driver was reversed — weight loss, opioid cessation, treated sleep apnea — may retest after a 6 to 12 week washout.

  • Stopping for a safety signal: Hematocrit above 54%, a new clot, an unexplained prostate-specific antigen rise or new atrial fibrillation prompt interruption rather than taper, given the harms are concentration-dependent.

Sourcing and Quality

  • Pharmaceutical-grade products only: Approved testosterone is a Schedule III controlled substance in the United States and prescription-only in most jurisdictions; underground-laboratory vials carry no assay, sterility or dose guarantee.

  • Carrier oil matters: Injectable esters are dissolved in sesame, cottonseed, castor or grapeseed oil. Sesame and cottonseed cause most injection-site reactions; a switch of carrier often resolves persistent pain or swelling.

  • Compounded versus manufactured: Compounded creams and injectables allow doses the approved products do not offer, but potency varies between pharmacies. Accreditation by the Pharmacy Compounding Accreditation Board is the usual quality marker.

  • Established manufacturers and compounders: AbbVie, Endo, Halozyme, Tolmar and Lipocine market approved products; Empower, Olympia and Belmar are commonly used accredited compounding pharmacies for creams and non-standard strengths.

  • Telehealth supply chains: Direct-to-consumer platforms ship from partner compounders whose accreditation and certificates of analysis vary; the prescribing clinic’s financial interest in continued therapy is itself a quality consideration.

  • Third-party testing: Manufactured products carry batch assays under regulatory oversight. For compounded material, a lot-specific certificate of analysis showing potency and sterility is the equivalent check.

Practical Considerations

  • Time to effect: Sexual desire and mood shift within 3 to 6 weeks and plateau by 6 weeks; red cell mass and body composition change over 3 to 12 months; bone density continues improving for up to 3 years.

  • Pitfall — measuring at the wrong time: Total testosterone varies across the day and between assays. Non-fasting afternoon samples and calculated free testosterone in men with abnormal carrier protein both produce misleading numbers.

  • Pitfall — chasing the top of the range: The dose-dependent harms scale with concentration while symptom relief plateaus, so pushing toward the upper limit buys erythrocytosis and acne without proportionate benefit.

  • Pitfall — starting without banking sperm: Fertility suppression is the harm men most often learn about too late; it is cheap to prevent beforehand and slow and uncertain to reverse afterward.

  • Regulatory status: Approved for classical hypogonadism only. Use for age-related decline with borderline values is off-label. In 2025 the United States regulator revised the class labeling in light of the large safety trial, adding a blood pressure warning.

  • Cost and access: Generic injectable cypionate is inexpensive, while branded gels and oral and long-acting injectable forms cost many times more. Access is limited less by price than by finding a prescriber willing to treat borderline values.

  • Structural incentives shaping the evidence: Insurers and health systems have a systematic incentive to favor cheap generic injections, while manufacturers of the costlier branded forms fund much of the comparative safety and convenience literature — a bias in guideline formation and research funding alike.

Interaction with Foundational Habits

  • Sleep: Bidirectional and potentiating in both directions. Short or fragmented sleep lowers endogenous testosterone, while replacement can transiently worsen existing obstructive sleep apnea. Practically, apnea is diagnosed and treated before starting, and restoring 7 to 9 hours raises endogenous output independently.

  • Nutrition: Indirect and enabling. Very low-fat diets and sustained energy deficits suppress endogenous production, and the oral undecanoate forms require dietary fat for absorption, so they are administered with a meal containing roughly 20 g. Adequate protein amplifies the lean-mass response.

  • Exercise: Potentiating and additive. Resistance training and testosterone act on the same muscle protein synthesis pathway, and the combination produces larger lean-mass and strength gains than either alone; graded-dose work shows strength rising with concentration in trained and untrained men alike.

  • Stress management: Indirect and blunting. Sustained cortisol elevation suppresses the hypothalamic signal driving testosterone output and opposes its anabolic effects at the muscle. Replacement overrides the upstream suppression but not the catabolic opposition, so stress reduction remains complementary rather than redundant.

Monitoring Protocol & Defining Success

Before the first dose, two separate fasting morning blood draws establish total testosterone, with sex hormone-binding globulin, luteinizing hormone, follicle-stimulating hormone and prolactin to identify whether the defect sits in the testes or the pituitary. A complete blood count, prostate-specific antigen with digital rectal examination, a comprehensive metabolic panel, a lipid panel, glycated hemoglobin, blood pressure and — where fatherhood is possible — a semen analysis complete the baseline. Ongoing monitoring follows a front-loaded cadence: hematocrit, total testosterone and blood pressure at 6 to 8 weeks, a full panel at 3 and 6 months, then every 6 to 12 months indefinitely. Prostate-specific antigen is repeated at 3 to 12 months and annually thereafter. Bone density is reassessed every 2 years in men with a fracture history.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Total testosterone 500–800 ng/dL at trough (17.4–27.8 nmol/L) Confirms the dose reaches target Fasting, before 10 a.m., and immediately before the next dose; two baseline draws on separate days
Free testosterone 15–25 ng/dL by equilibrium dialysis The fraction actually available to tissues Calculated values are unreliable when carrier protein is abnormal; paired with total testosterone
Sex hormone-binding globulin 20–50 nmol/L Explains mismatch between total and free values Falls with insulin resistance and obesity; rises with age, thyroid excess and liver disease
Estradiol, mass-spectrometry assay 20–40 pg/mL Mediates bone and libido effects; excess causes breast tenderness Immunoassays overestimate in men; conventional male reference ranges are wider and less useful
Hematocrit 40–50%; action above 52% Erythrocytosis is the commonest dose-limiting effect Conventional upper limit is 54%; functional action threshold is lower. Sleep apnea raises it further
Hemoglobin 13.5–16.5 g/dL Tracks red cell mass alongside hematocrit Rises 0.8–1.0 g/dL on average; a larger rise signals over-dosing
Prostate-specific antigen Below 1.5 ng/mL under 60; below 2.5 ng/mL over 60 Detects prostate growth or disease before and during therapy PSA is prostate-specific antigen. Conventional cut-off is 4.0 ng/mL; a rise above 1.4 ng/mL in a year prompts referral regardless
Luteinizing hormone and follicle-stimulating hormone Baseline: LH above 9 IU/L indicates testicular failure Distinguishes testicular from pituitary cause; confirms suppression on therapy LH is luteinizing hormone, FSH follicle-stimulating hormone. Measured at baseline and after stopping, not routinely during therapy
Blood pressure, home or 24-hour ambulatory Below 120/80 mmHg Testosterone raises systolic pressure by several mmHg Weekly home readings for 3 months; ambulatory monitoring where the rise is borderline
Apolipoprotein B Below 80 mg/dL; below 60 mg/dL at high risk Counts atherogenic particles; testosterone lowers HDL cholesterol ApoB is apolipoprotein B. Fasting is not required; conventional panels report low-density lipoprotein cholesterol instead, which is less informative
Glycated hemoglobin 4.8–5.4% Tracks the glucose-tolerance benefit HbA1c is glycated hemoglobin. Conventional threshold for concern is 5.7%; paired with fasting insulin
Estimated glomerular filtration rate Above 90 mL/min/1.73 m² Kidney injury appeared as a safety signal in the largest trial eGFR is estimated glomerular filtration rate. Creatinine rises modestly with added muscle mass; cystatin C avoids that artifact
Sperm concentration Above 15 million/mL where fertility matters Exogenous testosterone suppresses sperm production Baseline before the first dose when fatherhood is planned; cryopreservation at the same visit
Bone mineral density by dual-energy X-ray absorptiometry T-score above −1.0 Bone is a target tissue and a documented safety signal DXA is dual-energy X-ray absorptiometry; the T-score compares density with a healthy young adult. Baseline where fracture history exists; repeated every 2 years

Qualitative markers tracked alongside the laboratory panel:

  • Frequency of spontaneous morning erections
  • Sexual desire and frequency of sexual thoughts
  • Daytime energy and sense of vitality
  • Mood stability, irritability and emotional volatility
  • Sleep quality and any new snoring or witnessed breathing pauses
  • Training performance, recovery between sessions and perceived strength
  • Waist circumference and visible body composition change
  • Cognitive clarity and capacity for sustained concentration

Emerging Research

  • Frailty and falls in older men: NCT07512323, a Phase 2 trial in 96 frail older men with testosterone deficiency, uses the chair-stand test as its primary endpoint — the functional outcome the earlier trials measured inconsistently.

  • Quantifying the blood pressure signal: NCT07328542, a Phase 4 study in 144 hypogonadal men sponsored by Azurity Pharmaceuticals, takes 24-hour ambulatory systolic pressure as its primary outcome, testing the harm the regulator singled out for labeling.

  • Unexplained fracture excess: Snyder et al., 2024 found more fractures despite higher bone density. Whether this reflects falls, bone quality or chance is the field’s clearest open question and could weaken the case substantially.

  • Cardiovascular safety beyond the largest trial: Braga et al., 2025 pooled long-term randomized cardiovascular data; Yeap et al., 2024 argue the next trial must enroll men without established cardiovascular disease, where the risk-benefit balance is unknown.

  • Combining testosterone with 5-alpha-reductase blockade: NCT07742553, a Phase 2/3 trial in 300 men after spinal cord injury, tests whether adding finasteride preserves lean-mass gains while limiting prostate and skin effects.

  • Whether low testosterone causes or merely marks poor outcomes: Yeap et al., 2024 pooled individual data on 255,830 participant-years, finding higher mortality below 7.4 nmol/L — an association that trials of the therapy have not converted into benefit.

Conclusion

Male hormone replacement therapy supplies testosterone from outside the body to men whose own production has fallen. The evidence for what it changes is now unusually good by the standards of longevity interventions. Sexual desire, lean tissue, bone density, red blood cell production and glucose handling all improve in controlled trials, and the improvements are substantial rather than marginal. Everyday physical function, mood and thinking respond much less consistently, and nothing in the trial record shows that the therapy lengthens life.

The harms are equally well characterized and mostly dose-related. Thickened blood is the common one and the usual reason doses are reduced. Sperm production stops and the body’s own hormone output shuts down, both slow and sometimes incomplete to reverse. The largest safety trial cleared the heart-attack concern that dominated the field for a decade, yet the same trial raised new questions about fractures, irregular heart rhythm, clotting in the lungs and kidney injury that remain unresolved.

Two things temper confidence in this evidence. Much of the decisive trial work was paid for by the companies selling testosterone, and the professional bodies and men’s-health clinics setting practice earn from prescribing and monitoring it. Cost differences between cheap generic injections and costly branded forms give payers and manufacturers opposing incentives that shape which questions get funded. For a man weighing this deliberately, the trade is a reliable set of measurable gains against a set of manageable harms and a handful of genuinely open safety questions.

Top - Benefits - Risks - Protocol